DAVITA INC. Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest
DAVITA INC. (DVA) reported Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest of $158.67 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Shareholders' Equity
us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest · last filed 2020-10-29
- DAVITA INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2020-09-30 was $158.67M, a 10.75% increase year-over-year.
- DAVITA INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2020-06-30 was $201.60M, a 26.30% decline year-over-year.
- DAVITA INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2020-03-31 was $239.59M, a 60.49% increase year-over-year.
- DAVITA INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2019-12-31 was $244.87M.
- DAVITA INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for fiscal 2019 was $810.98M, a 408.79% increase from fiscal 2018.
- DAVITA INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for fiscal 2018 was $159.39M, a 75.98% decline from fiscal 2017.
- DAVITA INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for fiscal 2017 was $663.62M, a 24.58% decline from fiscal 2016.
- DAVITA INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for fiscal 2016 was $879.87M.
| Period end | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2020-09-30 | $158.67M 10-Q · filed 2020-10-29 | $360.28M derived: sum of 2 quarters · filed 2020-10-29 | $599.87M 10-Q · filed 2020-10-29 | $844.74M derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-06-30 | $201.60M 10-Q · filed 2020-07-30 | $441.19M 10-Q · filed 2020-07-30 | $686.07M derived: sum of 3 quarters · filed 2020-07-30 | $829.34M derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-03-31 | $239.59M 10-Q · filed 2020-05-05 | $484.46M derived: sum of 2 quarters · filed 2020-05-05 | $627.73M derived: sum of 3 quarters · filed 2020-10-29 | $901.28M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-12-31 | $244.87M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $388.14M derived: sum of 2 quarters · filed 2020-10-29 | $661.69M derived: sum of 3 quarters · filed 2020-10-29 | $810.98M 10-K · filed 2020-02-21 |
| 2019-09-30 | $143.27M 10-Q · filed 2020-10-29 | $416.82M derived: sum of 2 quarters · filed 2020-10-29 | $566.11M 10-Q · filed 2020-10-29 | $416.34M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | $273.55M 10-Q · filed 2020-07-30 | $422.84M 10-Q · filed 2020-07-30 | $273.07M derived: sum of 3 quarters · filed 2020-07-30 | $136.27M derived: sum of 4 quarters · filed 2020-07-30 |
| 2019-03-31 | $149.29M 10-Q · filed 2020-05-05 | -$483.00K derived: sum of 2 quarters · filed 2020-05-05 | -$137.28M derived: sum of 3 quarters · filed 2020-05-05 | $130.00M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-31 | -$149.77M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | -$286.57M derived: sum of 2 quarters · filed 2020-02-21 | -$19.29M derived: sum of 3 quarters · filed 2020-02-21 | $159.39M 10-K · filed 2020-02-21 |
| 2018-09-30 | -$136.80M 10-Q · filed 2019-11-07 | $130.48M derived: sum of 2 quarters · filed 2019-11-07 | $309.17M 10-Q · filed 2019-11-07 | $612.56M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $267.28M 10-Q · filed 2019-08-02 | $445.96M 10-Q · filed 2019-08-02 | $749.36M derived: sum of 3 quarters · filed 2020-02-21 | $534.88M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $178.69M 10-Q · filed 2019-05-07 | $482.08M derived: sum of 2 quarters · filed 2020-02-21 | $267.61M derived: sum of 3 quarters · filed 2020-02-21 | $394.61M derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $303.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $88.92M derived: sum of 2 quarters · filed 2020-02-21 | $215.92M derived: sum of 3 quarters · filed 2020-02-21 | $663.62M 10-K · filed 2020-02-21 |
| 2017-09-30 | -$214.48M 10-Q · filed 2018-11-07 | -$87.47M derived: sum of 2 quarters · filed 2018-11-07 | $360.22M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $127.00M 10-Q · filed 2018-08-01 | $574.70M 10-Q · filed 2018-08-01 | ||
| 2016-12-31 | $879.87M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |